Arbutus Biopharma
ABUS
167 hedge funds and large institutions have $390M invested in Arbutus Biopharma in 2025 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 46 increasing their positions, 52 reducing their positions, and 9 closing their positions.
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
37% more call options, than puts
Call options by funds: $3.1M | Put options by funds: $2.26M
15% more capital invested
Capital invested by funds: $340M → $390M (+$49.8M)
9% more funds holding
Funds holding: 153 → 167 (+14)
3.45% more ownership
Funds ownership: 54.92% → 58.38% (+3.5%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
12% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FC
Foursixthree Capital
New York
|
+$8.17M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$5.62M |
| 3 |
Goldman Sachs
New York
|
+$5.15M |
| 4 |
Morgan Stanley
New York
|
+$4.02M |
| 5 |
TSC
Two Seas Capital
Rye,
New York
|
+$2.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$2.21M |
| 2 |
JP Morgan Chase
New York
|
-$1.19M |
| 3 |
BlackRock
New York
|
-$570K |
| 4 |
Squarepoint
New York
|
-$536K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$517K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$18.3K | -5,450 | Closed |
|
|
AAP
177
Arax Advisory Partners
Denver,
Colorado
| – | -$3.94K | -1,206 | Closed |
|
ABUS Hedge Fund Activity: Q1 2025 in Review
167 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2025, worth a combined $390M — up 15% from $340M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new ABUS positions and 9 closed out — a net gain of 16 holders — while 46 added to existing stakes and 52 trimmed.
The largest buyer was Foursixthree Capital, opening a new position worth an estimated $8.17M. The largest seller was State Street, cutting an estimated $2.21M.
- 167 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2025, up from 153 in Q4 2024.
- Funds reported $390M of Arbutus Biopharma stock for Q1 2025, up 15% quarter-over-quarter.
- 25 funds opened new Arbutus Biopharma positions in Q1 2025 and 9 closed out, a net change of +16 holders.
- The largest Arbutus Biopharma buyer in Q1 2025 was Foursixthree Capital, an estimated $8.17M added.
- The largest Arbutus Biopharma seller in Q1 2025 was State Street, an estimated $2.21M sold.
Based on aggregated 13F filings for Q1 2025.